柏巴胺可以防止SARS-CoV-2进入和传播
Srikanth Sadhu1,2, Sandeep Goswami1,2, Ritika Khatri3
1Immuno-biology Lab, Infection and Immunology Centre, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, Haryana 121001, India.
iScience
|December 6, 2024
概括
柏柏林对SARS-CoV-2及其变体具有广泛的抗病毒活性. 这种化合物抑制病毒的进入,并增强免疫反应,可能防止传播和治疗感染.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 有效的抗病毒疗法对于管理COVID-19和预防未来的流行病至关重要.
- 许多化合物在体外表现出抗病毒活性,但很少在体内对SARS-CoV-2有效.
- 识别广泛的抗病毒药物是公共卫生的优先事项.
研究的目的:
- 评估贝巴胺 (Berb) 对SARS-CoV,MERS-CoV,SARS-CoV-2及其变体的疗效.
- 在体内阐明贝巴胺对SARS-CoV-2的作用机制.
- 评估贝巴胺在组合治疗和预防病毒传播中的潜力.
主要方法:
- 测试贝巴胺对各种贝塔冠状病毒,包括SARS-CoV-2变种,如XBB.1.16.6.
- 在 hACE2.Tg小鼠中研究贝巴的抗病毒机制,重点关注病毒进入和宿主基因表达.
- 评价与雷梅西维尔,克洛法西明和芳诺林的联合疗法.
- 评估贝巴胺对共住小鼠模型中的病毒分泌和传播的影响.
主要成果:
- 柏巴胺显示对SARS-CoV,MERS-CoV,SARS-CoV-2及其变体,包括XBB.1.16.1的有效性.
- 在小鼠中,贝巴胺抑制了尖端介导的病毒进入,并增强了抗病毒基因表达.
- 与贝巴胺,雷姆迪西维尔,克洛法齐明和方奇诺林的联合治疗几乎消除了病毒载量和改善了恢复.
- 柏巴胺的使用减少了病毒分泌和肺病理,这表明它在阻碍传播方面发挥了作用.
结论:
- 柏巴胺对临床相关的贝塔冠状病毒具有广泛的抗病毒活性.
- 柏巴胺具有针对SARS-CoV-2的双重作用机制,准病毒的进入并增强先天免疫力.
- 与贝巴胺的联合治疗显示出治疗急性SARS-CoV-2感染的显著潜力.
- 柏巴胺可以作为一种有前途的预防或治疗药物,对抗贝塔冠状病毒感染和传播.
相关概念视频
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.6K
01:19Depolarizing Blockers: Pharmocokinetics
305
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
305
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
391
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
391
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
248
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
248